SecureLink Named One of Inc. 5000’s Fastest-Growing Private Companies in the U.S.
August 17, 2021 07:42 ET
|
SecureLink
AUSTIN, Texas, Aug. 17, 2021 (GLOBE NEWSWIRE) -- SecureLink, a leader in third-party security, ranked 2645 on Inc. Magazine’s 2021 list of the fastest-growing private companies in the United States....
Intel 471 Named to the 2021 Inc. 5000 Annual List of the Fastest-Growing Companies in America
August 17, 2021 07:00 ET
|
Intel 471
LEWES, Del., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Intel 471, the premier provider of cybercrime intelligence for leading intelligence, security, and fraud teams, today revealed that it has earned a...
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET
|
Atea Pharmaceuticals, Inc.
New Data in Healthy Volunteers Confirmed that AT-527’s Active Metabolite Achieved Target Antiviral Levels in Lungs, Key Site of COVID-19 Infection AT-527 Phase 2 Study Interim Results Showed Potent...
Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021
August 05, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference
July 12, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics...
Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis
June 30, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting AT-527 is Being Studied in Multiple Clinical...
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche
June 16, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics...
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs
June 15, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral...
Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 26, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics...
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors
May 20, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections,...